Summary & Overview
CPT 80354: Fentanyl Detection in Patient Specimen
CPT code 80354 is a laboratory code used to report testing that measures or detects the presence of fentanyl in a patient specimen. Nationally, fentanyl testing plays a critical role in clinical toxicology, opioid stewardship, emergency medicine, and forensic evaluation because of fentanyl's potency and public health impact. Accurate identification of fentanyl influences clinical management, overdose response, and surveillance.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of service context, common payer coverage patterns, and the clinical rationale for fentanyl testing. The publication summarizes benchmark considerations for laboratory billing, typical sites of service, and practical coding context tied to CPT code 80354.
This resource provides clinicians, laboratory managers, and billing professionals with a clear description of the code, its clinical use, and the payer landscape to inform billing and administrative workflows. Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, and related codes are noted where applicable.
Billing Code Overview
CPT code 80354 describes a laboratory test in which a lab analyst measures the amount of or detects the presence of fentanyl in a patient specimen. The service type is toxicology testing / drug detection. The typical site of service is a clinical laboratory performing specimen analysis, which may include hospital labs, independent reference laboratories, and outpatient laboratory collection sites.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an emergency department or outpatient clinic with suspected fentanyl exposure, overdose, or for monitoring of opioid therapy and illicit drug screening. A clinician orders a urine or serum drug screen targeted for fentanyl quantitation or confirmation. The specimen is collected in the clinical laboratory, logged, and sent to the toxicology laboratory where a lab analyst performs testing using immunoassay screening followed by confirmatory techniques such as gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS) to detect and/or quantify fentanyl and its primary metabolite norfentanyl. Results are reported back to the ordering provider for clinical decision-making, which may include reversal of overdose with naloxone, adjustment of prescribed opioid therapy, or referral to substance use treatment. Typical sites of service include hospital inpatient laboratories, emergency departments, outpatient hospital-based clinics, and independent clinical laboratories performing toxicology testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation component if separated from the technical component |
TC |